Most Recent
The Australian Securities and Investments Commission has filed civil penalty proceedings against advisory firm Lanterne Fund Services, alleging it ran a “wholly deficient business”.
A judge overseeing a defamation case brought by Tolga Kumova against Twitter personality Stock Swami has said tweets the mining investor published which allegedly spruiked shares in which he invested were “clearly apt to mislead”.
A judge has questioned the Finance Sector Union’s idea to use a survey to gather evidence about 3,000 employees who claim the Commonwealth Bank of Australia failed to provide them with paid rest breaks for at least six years.
Virgin Australia will seek to throw out a case brought by former employees over a COVID-19 vaccine mandate, which a lawyer for Qantas and Jetstar, which are also named in the suit, said “breaks every pleading rule”.
Mining investor Tolga Kumova is “likely” to go after Twitter personality Stock Swami for contempt of court after he admitted he lied and withheld evidence in a defamation case, despite a judge saying there was “no smoking gun”.
AIG can't force investment firm Sayers to hand over communications over which it claimed legal professional privilege, with a judge rejecting the argument that Sayers could not “cherry pick” which advice it disclosed after waiving privilege over advice given by two barristers in 2017 and 2019.
Litigation funder Embedded Claims has filed court proceedings against one of its shareholders after its former bankrupt director “ineffectively” transferred off half of his shares.
A man who says he was falsely accused by a Seven journalist of spitting at an alleged rape victim of rugby league footballer Jarryd Hayne must hand over key CCTV footage he claims vindicates him in his defamation suit against Seven.
Twitter personality Alan Davison, who runs the account Stock Swami, has admitted he misled lawyers for mining investor Tolga Kumova and deliberately failed to obey court orders for discovery in cross-examination during a defamation trial.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.